Jan Adams Appointed Chief Scientific Officer for Grünenthal

Aachen, Germany (ots/PRNewswire) - Grünenthal announced today that Jan Adams, MD
has been appointed Chief Scientific Officer (CSO) and Member of the Corporate
Executive Board effective 1 January 2020. Since July 2019, Jan has already
served as acting CSO, leading the strategic re-alignment of Grünenthal's R&D
organisation.

Jan brings over 15 years of experience in healthcare and the biopharmaceutical
industry. He joined Grünenthal in July 2017 as Head Corporate Strategy and
Portfolio Management, working at the interface between strategy, research,
development and commercial. Prior to joining Grünenthal, he served as a member
of the global R&D Leadership Team at Takeda in Boston, where he held the
position of Head Strategic Management & Planning. Previously, Jan was a leader
in McKinsey & Company's global Pharmaceutical and Medical Products practice
working with clients in Europe, US and Asia. He started his career as a resident
in cardiology and a project leader in Clinical Development and Medical Affairs
at Novartis. Jan is a Medical Doctor by training, married and has two children.

"I'm very happy to continue working with Jan as CSO. He has accompanied us
through our transformation process and led the development and implementation of
our new R&D strategy and operating model, which puts us in an even stronger
position to deliver meaningful innovation to patients and live up to our vision
of a world free of pain," Gabriel Baertschi, Grünenthal CEO, said. "I'm glad to
welcome Jan as a new member of the Corporate Executive Board. I firmly believe
that his appointment will give Grünenthal's new R&D organisation continuity
after a major transformation and sets us up for success to fully execute on our
strategy," Wilhelm Moll, Chairman of the Supervisory Board, added.

"I am very much looking forward to continuing my work at Grünenthal as Chief
Scientific Officer and to further building our pipeline of highly innovative
assets addressing the high unmet medical needs in the area of pain," Jan Adams,
Grünenthal CSO, said. "Research and Development is at the core of our strategy
and we drive promising assets with a wide range of therapeutic modalities and a
strong network around the globe."

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a
science-based, privately-owned pharmaceutical company, we have a long track
record of bringing innovative treatments and state-of-the-art technologies to
patients worldwide. Our purpose is to change lives for the better - and
innovation is our passion. We are focussing all of our activities and efforts on
working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30
countries across Europe, Latin America and the US. Our products are available in
more than 100 countries. In 2018, Grünenthal employed around 4,900 people and
achieved sales of EUR 1.3 bn.

Photo: https://mma.prnewswire.com/media/1042754/Jan_Adams.jpg

More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Twitter: @grunenthalgroup
Instagram: grunenthal

For further information please contact:
St?pán Krá?ala, Head Global Communications
Phone: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Additional content: https://www.presseportal.de/pm/118252/4464153
OTS: Grünenthal Group

Original-Content von: Grünenthal Group, übermittelt durch news aktuell